spacer
home > ebr > Summer 2010
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2010
   
Text
PDF
BioBusiness, Finance & Communication
Geographic ‘clusters’ of companies and institutions that share the same interests can prove to be a more fluid way of achieving desired targets when faced with global markets and competition, finds Christian Garbe at FIZ Frankfurt Biotechnology Innovation Center.  
view
download pdf
The pharma business model is changing, requiring companies to achieve a higher base level in core competencies and to adapt to the more complex demands of current deals and transactions, explain Andrew Jones and Leo Gribben at Ernst & Young.  
view
download pdf
In today’s world, pharmaceutical publicity offices must adapt to rapid media developments as they occur.Donna L LaVoie of LaVoie Group summarises strategic steps for integrated partner communications.  
view
download pdf
Malcolm Young at e-Therapeutics plc and Alan Whitmore at Lumemed Ltd discuss how awareness of the potential advances in research is essential if businesses want to access truly up-to-date technologies, and avoid being left behind in the marketplace.  
view
download pdf
bullet
BioResearch and Innovation
Autoimmune diseases are responsible for a significant share of the European pharma market, and offer a considerable opportunity to those willing to innovate and meet regulatory standards, argues Suraj Ramanathan at GBI Research.  
view
download pdf
Critical limb ischaemia and related conditions are facing a powerful weapon in the form of placentalderived mesenchymal stromal cells. William R Prather at Pluristem Therapeutics, Inc reports on the advances which are underway in this field.  
view
download pdf
bullet
Discovery Technology
Juliet A Ellis and Francesco Muntoni at University College, London review developments in current research in RNA therapy, and explain its importance in the treatment of rare genetically determined diseases, particularly those affecting the central nervous system and muscle groups.
 
view
download pdf
Repositioning offers a cost-effective shortcut in the drug discovery process, yet for a variety of reasons it is nowhere near as commonly employed as it should be, shows Raúl Insa at SOM Biotech through discussion of several key examples of successfully repositioned drugs.
 
view
download pdf
Protein aggregation can have a decisive part to play in the quality and stability of biopharmaceutical products, with nanoparticle tracking analysis giving manufacturers greater control over this factor, explain Bob Carr and Andrew Malloy at NanoSight Limited.
 
view
download pdf
Rohan A Thakur and Michael Koleto at Taylor Technology discuss mass spectrometry, providing a detailed view of its uses and advantages, and demonstrating its potential for fast pharmacokinetic and semi-quantitative analysis of metabolites.
 
view
download pdf
bullet
BioDevelopment and Regulatory
Rasika Ramachandran at Frost & Sullivan points out the benefits of using stratified medicine in drug discovery trials, and highlights how biomarkers have a big part to play in their effective implementation.  
view
download pdf
Eleanor Root and Patrick Kelleher of Bird & Bird outline the existing regulatory infrastructure of biotechnology patent, including European rules, and provide examples that highlight the key issues.  
view
download pdf
Lee Caffin and Vandana Mamidanna at Think IP Strategy assert the necessity of research into the patent background surrounding any discovery or innovation programme, and advise on how to spot risky situations.  
view
download pdf
bullet
BioFormulation and Manufacturing
There is massive potential for transgenic plants to assist in the production of pharmaceutical proteins. Kathleen L Hefferon at Cornell Research Foundation explains how plant-derived products can be safer, more effective, and cheaper to produce.

 
view
download pdf
Biopharmaceutical manufacturing provides more than just cost-effectiveness; Eric S Langer at BioPlan Associates, Inc discusses the range of benefits it has to offer and covers some of the developments in this area in the last year.
 
view
download pdf
Christopher Stewart at MPI Research outlines recent progress in biologics and offers some insight into the effect this has had on small molecule development, encompassing current regulations along the way.
 
view
download pdf
bullet
BioRegional
Steeped in a history of medical innovation and discovery, Scotland continues to be a prime location for the biotech and biopharmaceutical industries, as Rhona Allison at Scottish Enterprise reports.
 
view
download pdf
Timur Bondaryev and Svitlana Ivasenko at Arzinger show how, despite suffering as a result of the recent economic slump, Ukraine is making progress in the biotechnology sector, with plenty of examples of growth to be seen.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Sterling Pharma Solutions launches following management buyout


More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

Industry Events

7th American Drug Delivery & Formulation Summit

28-29 August 2017, The Westin Copley Place Boston Hotel

Innovative solutions to the greatest challenges in pharmaceutical development
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement